x
Filter:
Filters applied
- Commentaries
- Hurt-Camejo, EvaRemove Hurt-Camejo, Eva filter
- 2017 - 2022Remove 2017 - 2022 filter
JLR Commentaries
1 Results
- CommentaryOpen Access
ANGPTL3, PCSK9, and statin therapy drive remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model
Journal of Lipid ResearchVol. 61Issue 3p272–274Published online: January 24, 2020- Eva Hurt-Camejo
Cited in Scopus: 6The current focus of therapeutic intervention to reduce atherosclerotic cardiovascular disease (ACVD) risk is lowering plasma LDL-C to below 70 mg/dl using primarily statins. However, many patients on statins remain at high ASCVD risk (1). Monoclonal antibodies against PCSK9, in addition to statins, can further reduce LDL-C. Also, Mendelian randomization reports show that moderately elevated triglyceride-rich lipoproteins and remnant cholesterol increase ASCVD risk independently of LDL-C levels (2).
